BDBM327106 N-{l-[4-(2,3-dihydro-1,4- benzodioxin-2- yl)benzyl]piperidin-4- yl}methanesulfonamide::US9662339, 48
SMILES: CS(=O)(=O)NC1CCN(Cc2ccc(cc2)C2COc3ccccc3O2)CC1
InChI Key: InChIKey=ZGQPTTFROJXZMQ-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Leukotriene A4 hydrolase (Homo sapiens (Human)) | BDBM327106 (N-{l-[4-(2,3-dihydro-1,4- benzodioxin-2- yl)benz...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.160 | n/a | n/a | n/a | n/a | n/a | n/a |
Boehringer Ingelheim International GmbH US Patent | Assay Description The compounds of the invention are assessed for the ability to interact with human LTA4 hydrolase in an enzymatic assay that measures the ability of ... | US Patent US9662339 (2017) BindingDB Entry DOI: 10.7270/Q2GT5Q8D | |||||||||||
More data for this Ligand-Target Pair |